You are here: Industry Insights > Harbour

News List

HBM Presents Phase I Data on Next-Generation Anti-CTLA-4 Antibody at ESMO Congress 2021 prnasia
July 27, 2021
Harbour BioMed announced that the abstract detailing clinical data from its Australian phase I study of next-generation anti-CTLA-4 antibody in patients with advanced solid tumors will be presented as an e-poster at the 2021 European Society for ...
Harbour BioMed Reports Positive Topline Results from Phase 2 Trial of Batoclimab (HBM9161) in Generalized Myasthenia Gravis prnasia
July 07, 2021
Harbour BioMed announced positive topline results from its Phase 2 proof-of-concept clinical trial of batoclimab (HBM9161) in Chinese generalized myasthenia gravis (gMG) patients.
Harbour BioMed Announces Dosing of First Patient of Next-Generation Anti-CTLA-4 Antibody in Combination with PD-1 Antibody in Patients with NSCLC prnasia
June 17, 2021
Harbour BioMed today announced the dosing of the first patient of HBM4003 in patients with advanced non-small cell lung cancer in its open phase I clinical study.
Harbour BioMed and Dana-Farber Cancer Institute Collaborate to Advance Novel Biotherapies for Cancer Treatment prnasia
June 16, 2021
Harbour BioMed announced today it has entered into a multi-year, multifaceted research collaboration agreement with Dana-Farber Cancer Institute to co-develop novel biotherapies in cancer treatment.
Harbour BioMed Announces Dosing of First Patient in Australia for Phase Ib/IIa Clinical Study of its Next-Generation Anti-CTLA-4 Antibody prnasia
May 12, 2021
Harbour BioMed announced the dosing of the first patient in its part 2 of phase I (phase Ib/IIa) clinical study of its next-generation anti-CTLA-4 antibody, where Australian patients with metastatic or advanced melanoma, hepatocellular carcinoma (HCC) ...
Harbour BioMed Presents Novel Antibody for Cancer Immunotherapy at 2021 American Association for Cancer Research Annual Meeting prnasia
April 13, 2021
Harbour BioMed, a global clinical-stage biopharmaceutical company, presents its newly discovered fully human anti-B7H7 monoclonal antibody at the American Association for Cancer Research Annual Meeting.
Harbour BioMed Announces Dosing of First Patient in Phase I Clinical Study of its Next-Generation Anti-CTLA-4 Antibody in China prnasia
March 22, 2021
Harbour BioMed (HBM) today announced the dosing of the first patient in its open Phase I clinical study of HBM4003 for Chinese patients suffering from advanced melanoma and other solid tumors (study No. 4003.2).
Harbour BioMed Doses First Patient in Tanfanercept Trial americanpharmaceuticalreview
March 19, 2021
Harbour BioMed announced the dosing of the first patient in the Phase III clinical trial of its global investigational tumor necrosis factor (TNF) receptor-1 fragment-based drug Tanfanercept (HBM9036) for adult patients with moderate-to-severe dry eye ...
Harbour BioMed Announces Dosing of First Patient in Tanfanercept Phase III Clinical Trial prnasia
March 12, 2021
Harbour BioMed today announced the dosing of the first patient in the Phase III clinical trial of its new global investigational tumor necrosis factor (TNF) receptor-1 fragment-based drug Tanfanercept (HBM9036) for adult patients with ...
Harbour BioMed's Batoclimab (HBM9161) Receives China CDE Breakthrough Therapy Designation for Treatment of Adult Patients with Myasthenia Gravis prnasia
January 28, 2021
Harbour BioMed (HBM), announced today that China Center for Drug Evaluation (CDE) has granted Breakthrough Therapy designation to Batoclimab (HBM 9161), a fully human anti-FcRn monoclonal antibody (mAb), for the treatment of adult patients with ...

Previous page 1 2 Next page